What is AIGEN Sciences?
Founded in 2021 and headquartered in Seoul, South Korea, AIGEN Sciences Inc. is at the forefront of AI-driven drug discovery. The company has developed a sophisticated platform designed to identify high-potency drugs. Its technology enables the direct discovery of compounds that induce desired cellular-level activity while minimizing off-target effects and toxicity, positioning AIGEN Sciences as a key innovator in pharmaceutical research and development.
How much funding has AIGEN Sciences raised?
AIGEN Sciences has raised a total of $8.8M across 1 funding round:
Series A
$8.8M
Series A (2024): $8.8M with participation from Partners Investment, Quad Investment Management, and Premier Partners
Key Investors in AIGEN Sciences
Partners Investment
Partners Investment is a South Korean private equity and venture capital firm that specializes in buyouts and startup investments, with a focus on information technology and biotechnology sectors.
Quad Investment Management
Quad Investment Management is an independent investment manager overseeing significant equity assets, known for its focus on differentiated portfolio management services and expanding its investment scope.
Premier Partners
Premier Partners, associated with Vimexx, offers domain registration, web hosting, and robust server solutions, catering to individuals and businesses establishing an online presence.
What's next for AIGEN Sciences?
With this substantial backing, AIGEN Sciences is poised for accelerated growth and expansion. The enterprise-level funding suggests a strategic phase focused on scaling operations, advancing its drug pipeline, and potentially forging new partnerships within the biotechnology and pharmaceutical sectors. The company's focus on precision and safety in drug discovery aligns with current industry trends, indicating a strong trajectory for future development and market penetration.
See full AIGEN Sciences company page
